Press release
Kaposi Sarcoma Pipeline Insight | Companies- Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and Others
To explore more information on the latest breakthroughs in the Kaposi Sarcoma Pipeline treatment landscape of the report, click here @ Kaposi Sarcoma Pipeline Outlook- https://www.delveinsight.com/sample-request/kaposis-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key takeaways from the Kaposi Sarcoma Pipeline Report
• Over 5+ Kaposi Sarcoma companies are evaluating 5+ Kaposi Sarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Kaposi Sarcoma market would significantly increase market revenue.
• The leading Kaposi Sarcoma Companies includes Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and others.
• Promising Kaposi Sarcoma Pipeline Therapies includes ABC294640, aldoxorubicin, Maraviroc, Alitretinoin, Semaxanib, valganciclovir, and others.
• On May 14, 2020, the Food and Drug Administration expanded the use of pomalidomide (POMALYST, Celgene Corporation) to include treating adult patients with Kaposi sarcoma associated with AIDS following the failure of highly active antiretroviral therapy as well as Kaposi sarcoma in adult patients who are HIV-negative.
• The Kaposi Sarcoma Companies and academics are working to assess challenges and seek opportunities that could influence Kaposi's sarcoma R&D. The Kaposi Sarcoma pipeline therapies under development are focused on novel approaches to treat/improve Kaposi's sarcoma.
For further information, refer to the detailed Kaposi Sarcoma Unmet Needs, Kaposi Sarcoma Market Drivers, and Kaposi Sarcoma Market Barriers, click here for Kaposi Sarcoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/kaposis-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Kaposi Sarcoma Overview
Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face.
Request a sample and discover the recent advances in Kaposi Sarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Kaposi Sarcoma Treatment Landscape- https://www.delveinsight.com/sample-request/kaposis-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Kaposi Sarcoma Emerging Drugs Profile
• sEphB4-HAS: Vasgene Therapeutics
sEphB4-HSA functions as a decoy receptor for the membrane-bound ligand Ephrin-B2 (Efnb2) and interferes with the binding of Efnb2 to its native receptors, including EphB4 and EphA3. This may result in a reduction of angiogenesis and a reduction in cell growth of Efnb2 and/or EphB4 over-expressing tumor cells. Soluble EphB4-HSA inhibits the interaction between EphB4 receptor kinase and its cognate ligand EphrinB2 and bidirectional signaling. EphB4-EphrinB2 are expressed on venous and arterial endothelium and critically required for maturation of newly forming vessels. sEphB4 inhibits angiogenesis in response to various vascular growth promoting agents and thus has a broad and novel anti-angiogenic activity. EphB4 is also highly induced in many cancers and sEphB4 has direct tumor cell cytotoxicity. sEphB4-HSA thus may impact survival and quality of life of many cancer victims. The drug is currently being investigated in Phase II stage of development to treat Kaposi's sarcoma.
Dive deep into rich insights for drugs for Kaposi Sarcoma Market Drivers and Kaposi Sarcoma Market Barriers, click here @ Kaposi Sarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/kaposis-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Kaposi Sarcoma Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Kaposi's sarcoma. The companies which have their Kaposi's sarcoma drug candidates in the most advanced stage, i.e. phase II include, Vasgene Therapeutics.
Scope of the Kaposi Sarcoma Pipeline Report
• Coverage- Global
• Kaposi Sarcoma Companies- Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and others.
• Kaposi Sarcoma Pipeline Therapies- ABC294640, aldoxorubicin, Maraviroc, Alitretinoin, Semaxanib, valganciclovir, and others.
• Kaposi Sarcoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Kaposi Sarcoma Mergers and acquisitions, Kaposi Sarcoma Licensing Activities @ Kaposi Sarcoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/kaposis-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Kaposi's sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Kaposi's sarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. sEphB4-HAS: Vasgene Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NT-I7: NeoImmuneTech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CE-003: Cello Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Kaposi's sarcoma Key Companies
21. Kaposi's sarcoma Key Products
22. Kaposi's sarcoma- Unmet Needs
23. Kaposi's sarcoma- Market Drivers and Barriers
24. Kaposi's sarcoma- Future Perspectives and Conclusion
25. Kaposi's sarcoma Analyst Views
26. Kaposi's sarcoma Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Kaposi Sarcoma Pipeline Insight | Companies- Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and Others here
News-ID: 3067875 • Views: …
More Releases from DelveInsight Business Research
Neurotrophic Keratitis Market Report 2032: Epidemiology Data, Pipeline Therapies …
DelveInsight's "Neurotrophic Keratitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurotrophic Keratitis, historical and forecasted epidemiology as well as the Neurotrophic Keratitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurotrophic Keratitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratitis Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key…
Keratoconus Market to Exhibit Rapid Growth Rate During the Forecast Period (2023 …
DelveInsight's "Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Keratoconus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Keratoconus Market Forecast
https://www.delveinsight.com/sample-request/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Keratoconus…
Cancer Cachexia Market to Observe Impressive Growth During the Forecast Period ( …
DelveInsight's "Cancer Cachexia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology as well as the Cancer Cachexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Cancer Cachexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Cachexia Market Forecast
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Chemotherapy Induced Neutropenia Market is Expected to Expand at a Healthy Growt …
DelveInsight's "Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia…
More Releases for Kaposi
Kaposi Sarcoma Treatment Market Drivers
Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma…
Kaposi Sarcoma Treatment Market Competitive Landscape
Kaposi sarcoma is a malignant tumor disease majorly associated with skin, mucous membranes, lymph nodes, and other organs. Kaposi sarcoma causes lesions to grow in the skin, in the mucous membranes lining the mouth, nose, and throat, lymph nodes, and other organs. Human herpesvirus-8 (HHV-8) is majorly found in the lesion of all patients suffering from Kaposi sarcoma. However, patients with weakened immune systems by Acquired Immune Deficiency Syndrome (AIDS)…
Kaposi Sarcoma Market: High incidence of HIV/AIDS associated Kaposi sarcoma is o …
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of…
Kaposi Sarcoma Market Analysis & Trends 2024
The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in…
Kaposi Sarcoma Market Research Report 2024
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of…
Kaposi Sarcoma Market: Patent Expiry of Blockbuster Drugs for Treatment of Kapos …
Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the…
